This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 4441299 results found since Jan 2013.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future Approaches
Curr Pharm Des. 2022 Mar 25. doi: 10.2174/1381612828666220325102840. Online ahead of print.ABSTRACTChronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated polyradiculoneuropathy leading to disability via inflammatory demyelination of peripheral nerves. Various therapeutic approaches with different mechanisms of action are established for the treatment of CIDP. Of those, corticosteroids, intravenous or subcutaneous immunoglobulin, or plasma exchange are established first-line therapies as suggested by the recently revised EAN/PNS guidelines for the management of CIDP. In special cases, immuno...
Source: Current Pharmaceutical Design - March 27, 2022 Category: Drugs & Pharmacology Authors: Martin K R Sva čina Helmar C Lehmann Source Type: research

Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
Ther Adv Neurol Disord. 2023 Jan 2;16:17562864221137129. doi: 10.1177/17562864221137129. eCollection 2023.ABSTRACTDespite advances in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and other common autoimmune neuropathies (AN), still-many patients with these diseases do not respond satisfactorily to the available treatments. Repurposing of disease-modifying therapies (DMTs) from other autoimmune conditions, particularly multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD), is a promising strategy that may accelerate the establishment of novel treatment choices for A...
Source: Adv Data - January 9, 2023 Category: Epidemiology Authors: Felix Kohle Marinos C Dalakas Helmar C Lehmann Source Type: research

Multifocal enlargement and increased vascularization of peripheral nerves detected by sonography in CIDP: A pilot study.
CONCLUSION: Multiple nerve enlargements occur in CIDP showing a relation with a lower MRC sum-score, increased nerve vascularization and a higher total protein of the CSF. SIGNIFICANCE: Our findings of nerve enlargement and increased nerve vascularization may be tools to monitor disease activity in CIDP, but further studies are needed. PMID: 23880223 [PubMed - as supplied by publisher]
Source: Clinical Neurophysiology - July 20, 2013 Category: Neurology Authors: Goedee HS, Brekelmans GJ, Visser LH Tags: Clin Neurophysiol Source Type: research

Cytokine Profile in the Cerebrospinal Fluid of MS and CIDP Patients (P5.209)
CONCLUSIONS: This pilot study shows a different cytokine expression profile in the CSF of MS, CIDP, and NIND patients. Our findings support the concept that central and peripheral demyelination are independent and differentiated diseases, despite some common antigens.Disclosure: Dr. Sartori has nothing to disclose. Dr. Bonin has nothing to disclose. Dr. Comar has nothing to disclose. Dr. Fantini has nothing to disclose. Dr. Bratina has nothing to disclose. Dr. Moretti has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Sartori, A., Bonin, S., Comar, M., Fantini, J., Bratina, A., Moretti, R. Tags: MS and CNS Inflammatory Diseases: Biomarkers and Disease Mechanisms Source Type: research

Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy. An Electrodiagnostic Study (S42.005)
CONCLUSIONS: Although, there are several features that suggest the diagnosis of A-CIDP during the initial presentation, close follow up of GBS patients during the recovery phase is also needed for accurate diagnosis. EDX studies may distinguish patients with A-CIDP from GBS patients. Study Supported by: Case Western University Hospital, Neurology department, Neuromuscular Center.Disclosure: Dr. Anadani has nothing to disclose. Dr. Katirji has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Anadani, M., Katirji, B. Tags: New Developments in Peripheral Neuropathies Source Type: research

Diffusion tensor imaging of the brachial plexus and cervical spinal nerve roots: case control study in cidp patients and controls (p4.138)
Conclusions:Our preliminary data prove the clinical feasibility and reproductibility of DTI for the evaluation of plexus and cervical nerve roots in patients with CIDP.Disclosure: Dr. Chanson has nothing to disclose. Dr. Barriol has nothing to disclose. Dr. Taithe has nothing to disclose. Dr. Zerroug has nothing to disclose. Dr. Lhoste has nothing to disclose. Dr. Pereira has nothing to disclose. Dr. Boyer has nothing to disclose. Dr. jean has nothing to disclose. Dr. Clavelou has received personal compensation for activities with Sanofi Genzyme, Teva, Novartis, Almirall, and Biogen.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Chanson, E., Barriol, M., Taithe, F., Zerroug, A., Lhoste, A., Pereira, B., Boyer, L., jean, B., Clavelou, P. Tags: Neuromuscular and Clinical Neurophysiology (EMG): Peripheral Neuropathy I Source Type: research

Large coverage MR neurography in CIDP: diagnostic accuracy and electrophysiological correlation
The objective  of this study was to evaluate large coverage magnetic resonance neurography (MRN) in chronic inflammatory demyelinating polyneuropathy (CIDP). In this prospective study, 18 patients with CIDP and 18 healthy controls were examined by a standardized MRN protocol at 3 T. Lumbosacral plexus was image d by a T2-weighted 3D sequence and peripheral nerves of the upper and lower extremity by axial T2-weighted turbo spin-echo sequences. Lesions were characterized by nerve cross-sectional area (CSA) and T2-weighted signal (nT2). Additionally, T2 relaxometry of the sciatic nerve was performed using a m ulti-spin-echo...
Source: Journal of Neurology - June 15, 2017 Category: Neurology Source Type: research

Progress in Hematopoietic Stem Cell Transplantation for CIDP.
Authors: Qin Z, Huang Q, Zou J, Tang L, Hu Z, Tang X Abstract Chronic inflammatory demyelinating polyneuropathy (CIDP) is a kind of autoimmune-mediated inflammation and demyelinating disease. The etiology is mainly related to autoimmune dysfunction. The conventional treatments of CIDP have relied on immunomodulation and inhibition therapies such as adrenal cortex hormone, intravenous immunoglobulin (IVIg) and plasma exchange. Hematopoietic stem cell transplantation (HSCT) is known as a novel therapy for autoimmune disorders, which provides the chance to cure CIDP. More than 70 patients with refractory CIDP have rec...
Source: International Journal of Medical Sciences - February 12, 2020 Category: Biomedical Science Tags: Int J Med Sci Source Type: research

Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP
In conclusion, we can infer that excluding DML prolongation of median nerve does not increase the risk of missing a diagnosis of CIDP thus corroborating the current EFNS/PNS criteria.
Source: Journal of Neurology - January 23, 2022 Category: Neurology Source Type: research

CIDP-like autoimmune nodopathy complicated with focal segmental glomerulosclerosis: a case study and literature review
ConclusionsNF186 was probably a targeted antigen in the pathogenesis of concurrent FSGS in CIDP-like autoimmune nodopathy with positive NF186 antibody. CIDP-like autoimmune nodopathy with positive NF186 antibody and FSGS is a rare entity, which may be responsive to corticosteroids combined with immunosuppressant.
Source: Journal of Neurology - January 1, 2023 Category: Neurology Source Type: research

CIDP: Analysis of Immunomarkers During COVID-19 mRNA-Vaccination and IVIg-Immunomodulation: An Exploratory Study
This study was registered in the German clinical trial register (DRKS00025759).Graphical AbstractOverview over the study design. Blood samples of CIDP patients on recurrent IVIg treatment and vaccination with a COVID-19 mRNA vaccine were obtained at four timepoints for cytokine ELISA and flow cytometry, to assess key cytokines and cellular immunomarkers for disease activity and IVIg-immunomodulation in CIDP.
Source: Journal of NeuroImmune Pharmacology - March 16, 2023 Category: Drugs & Pharmacology Source Type: research

Clinical features of CIDP with LM1-associated antibodies
Conclusion In humans, LM1 is contained more in the dorsal root than in the cranial nerves. The clinical features of CIDP patients with antibodies to LM1 and LM1-containing complexes may be associated with the distribution of the LM1 antigen. LM1-associated antibodies are possible markers for a subclass of CIDP.
Source: Journal of Neurology, Neurosurgery and Psychiatry - April 8, 2013 Category: Neurosurgery Authors: Kuwahara, M., Suzuki, H., Samukawa, M., Hamada, Y., Takada, K., Kusunoki, S. Tags: Cranial nerves, Neuromuscular disease, Peripheral nerve disease Source Type: research

Home IVIG for CIDP: A Focus on Patient Centred Care.
Conclusion: Intravenous immunoglobulin can be delivered safely and is well tolerated outside the hospital setting in Canada in patients with chronic, stable neuromuscular conditions such as CIDP who have previously tolerated IVIG in the hospital medical day Care Unit. PMID: 23603176 [PubMed - in process]
Source: The Canadian Journal of Neurological Sciences - May 1, 2013 Category: Neurology Authors: Katzberg HD, Rasutis V, Bril V Tags: Can J Neurol Sci Source Type: research

Association of HLA-DR/DQ polymorphism with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Tunisian patients
Conclusion: To our knowledge, this is the first study performed to analyze the association of HLA-DRB1/DQB1 alleles on CIDP susceptibility in a Tunisian population.
Source: Transfusion and Apheresis Science - August 21, 2013 Category: Hematology Authors: Meriem Mrad, Najiba Fekih-Mrissa, Malek Mansour, Aicha Seyah, Anis Riahi, Nasreddine Gritli, Ridha Mrissa Tags: Submitted Papers Source Type: research